About the Company
We do not have any company description for FATE THERAPEUTICS INC at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on FATE THERAPEUTICS INC
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Fate Therapeutics Inc. faces a ...
Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $4 ...
Wells Fargo & Company dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th.
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data
Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc.
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.33 per share a year ago. These figures ...
Fate Therapeutics (NASDAQ:FATE) Share Price Crosses Below Two Hundred ...
Posted by MarketBeat News on Apr 4th, 2025 Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Thursday .
Fate Therapeutics Announces CFO Change and Shareholder Approvals
Fate Therapeutics, Inc. has announced the appointment of J. Scott Wolchko as the new Chief Financial Officer and principal financial and accounting officer, following the resignation of Edward J ...
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-clas ...
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Results Conference Call May 9, 2024 5:00 PM ETCompany ParticipantsScott Wolchko - President and CEOEd Dulac - ...
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and ...
Fate Therapeutics Inc. faces significant volatility in its stock price, independent of its operational performance, due to a multitude of factors including clinical trial outcomes, regulatory ...
Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A ... - Seeking Alpha
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors May 30, 2025 4:30 PM ET Neurocrine Biosciences, Inc. (NBIX), FATE ...
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for ...
Fate Therapeutics, Inc. (NASDAQ: FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy, at the ...
Similar Companies
Loading the latest forecasts...